• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实验模型中 NAFLD 和 NASH 的病理生理学:摄食调节肽的作用。

Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides.

机构信息

Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czechia.

Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.

出版信息

Front Endocrinol (Lausanne). 2020 Nov 26;11:597583. doi: 10.3389/fendo.2020.597583. eCollection 2020.

DOI:10.3389/fendo.2020.597583
PMID:33324348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7726422/
Abstract

Obesity, diabetes, insulin resistance, sedentary lifestyle, and Western diet are the key factors underlying non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases in developed countries. In many cases, NAFLD further progresses to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and to hepatocellular carcinoma. The hepatic lipotoxicity and non-liver factors, such as adipose tissue inflammation and gastrointestinal imbalances were linked to evolution of NAFLD. Nowadays, the degree of adipose tissue inflammation was shown to directly correlate with the severity of NAFLD. Consumption of higher caloric intake is increasingly emerging as a fuel of metabolic inflammation not only in obesity-related disorders but also NAFLD. However, multiple causes of NAFLD are the reason why the mechanisms of NAFLD progression to NASH are still not well understood. In this review, we explore the role of food intake regulating peptides in NAFLD and NASH mouse models. Leptin, an anorexigenic peptide, is involved in hepatic metabolism, and has an effect on NAFLD experimental models. Glucagon-like peptide-1 (GLP-1), another anorexigenic peptide, and GLP-1 receptor agonists (GLP-1R), represent potential therapeutic agents to prevent NAFLD progression to NASH. On the other hand, the deletion of ghrelin, an orexigenic peptide, prevents age-associated hepatic steatosis in mice. Because of the increasing incidence of NAFLD and NASH worldwide, the selection of appropriate animal models is important to clarify aspects of pathogenesis and progression in this field.

摘要

肥胖、糖尿病、胰岛素抵抗、久坐不动的生活方式和西方饮食是导致非酒精性脂肪性肝病(NAFLD)的关键因素,NAFLD 是发达国家最常见的肝脏疾病之一。在许多情况下,NAFLD 进一步发展为非酒精性脂肪性肝炎(NASH)、纤维化、肝硬化和肝细胞癌。肝脂肪毒性和非肝脏因素,如脂肪组织炎症和胃肠道失衡,与 NAFLD 的演变有关。如今,脂肪组织炎症的程度被证明与 NAFLD 的严重程度直接相关。摄入更高的热量越来越多地被认为是代谢炎症的燃料,不仅与肥胖相关疾病有关,也与 NAFLD 有关。然而,NAFLD 的多种病因是导致 NAFLD 进展为 NASH 的机制仍未被充分理解的原因。在这篇综述中,我们探讨了食物摄入调节肽在 NAFLD 和 NASH 小鼠模型中的作用。瘦素是一种厌食肽,参与肝脏代谢,对 NAFLD 实验模型有影响。胰高血糖素样肽-1(GLP-1),另一种厌食肽,和 GLP-1 受体激动剂(GLP-1R),是预防 NAFLD 进展为 NASH 的潜在治疗药物。另一方面,饥饿激素 ghrelin 的缺失可防止小鼠年龄相关性肝脂肪变性。由于全球范围内 NAFLD 和 NASH 的发病率不断上升,选择合适的动物模型对于阐明该领域发病机制和进展非常重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0fc/7726422/92c9cbe7e763/fendo-11-597583-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0fc/7726422/e96dae72689a/fendo-11-597583-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0fc/7726422/eb1c346463c6/fendo-11-597583-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0fc/7726422/92c9cbe7e763/fendo-11-597583-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0fc/7726422/e96dae72689a/fendo-11-597583-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0fc/7726422/eb1c346463c6/fendo-11-597583-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0fc/7726422/92c9cbe7e763/fendo-11-597583-g003.jpg

相似文献

1
Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides.实验模型中 NAFLD 和 NASH 的病理生理学:摄食调节肽的作用。
Front Endocrinol (Lausanne). 2020 Nov 26;11:597583. doi: 10.3389/fendo.2020.597583. eCollection 2020.
2
Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.非酒精性脂肪性肝病治疗在 2 型糖尿病患者中;新的问题出现了。
Curr Vasc Pharmacol. 2020;18(2):172-181. doi: 10.2174/1570161117666190405164313.
3
Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression.丁酸钠通过上调肝 GLP-1R 表达减轻高脂饮食诱导的非酒精性脂肪性肝炎。
Exp Mol Med. 2018 Dec 3;50(12):1-12. doi: 10.1038/s12276-018-0183-1.
4
GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.GLP-1 拟似物作为非酒精性脂肪性肝炎的一种潜在疗法。
Acta Pharmacol Sin. 2022 May;43(5):1156-1166. doi: 10.1038/s41401-021-00836-9. Epub 2021 Dec 21.
5
Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.GLP-1 受体激动剂对非酒精性脂肪性肝病和非酒精性脂肪性肝炎肝纤维化程度和 CRP 的影响:系统评价和荟萃分析。
Prim Care Diabetes. 2024 Jun;18(3):268-276. doi: 10.1016/j.pcd.2024.03.005. Epub 2024 Mar 30.
6
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!新型抗糖尿病药物对非酒精性脂肪肝和脂肪性肝炎的影响:另辟蹊径!
Metabolism. 2019 Dec;101:154001. doi: 10.1016/j.metabol.2019.154001. Epub 2019 Oct 28.
7
Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective.胰高血糖素样肽 1 和成纤维细胞生长因子 21 在非酒精性脂肪性肝炎中的作用:从实验到临床的视角。
Pharmacol Res. 2022 Oct;184:106426. doi: 10.1016/j.phrs.2022.106426. Epub 2022 Sep 6.
8
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.2型糖尿病合并非酒精性脂肪性肝病患者的治疗:当前方法与未来方向
Diabetologia. 2016 Jun;59(6):1112-20. doi: 10.1007/s00125-016-3952-1. Epub 2016 Apr 21.
9
The role of incretin hormones and glucagon in patients with liver disease.肠促胰岛素激素和胰高血糖素在肝病患者中的作用。
Dan Med J. 2017 May;64(5).
10
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.胰高血糖素样肽-1受体激动剂在非酒精性脂肪性肝病管理中的新作用
J Clin Endocrinol Metab. 2022 Jan 1;107(1):29-38. doi: 10.1210/clinem/dgab578.

引用本文的文献

1
Effectiveness of RESET care program: A real-world-evidence on managing non-alcoholic fatty liver disease through digital health interventions.RESET护理计划的有效性:通过数字健康干预措施管理非酒精性脂肪性肝病的真实世界证据。
World J Hepatol. 2025 Jan 27;17(1):101630. doi: 10.4254/wjh.v17.i1.101630.
2
Metabolic dysfunction-associated steatotic liver disease-induced changes in the antioxidant system: a review.代谢功能障碍相关脂肪性肝病引起的抗氧化系统变化:综述
Arch Toxicol. 2025 Jan;99(1):1-22. doi: 10.1007/s00204-024-03889-x. Epub 2024 Oct 23.
3
Contribution of extracellular vesicles to steatosis-related liver disease and their therapeutic potential.

本文引用的文献

1
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade.非酒精性脂肪性肝病的多重平行打击假说:十年后再审视
Hepatology. 2021 Feb;73(2):833-842. doi: 10.1002/hep.31518. Epub 2021 Feb 6.
2
Targeted Nutrient Modifications in Purified Diets Differentially Affect Nonalcoholic Fatty Liver Disease and Metabolic Disease Development in Rodent Models.纯化饮食中的靶向营养修饰对啮齿动物模型中非酒精性脂肪性肝病和代谢性疾病发展的影响各异。
Curr Dev Nutr. 2020 Apr 24;4(6):nzaa078. doi: 10.1093/cdn/nzaa078. eCollection 2020 Jun.
3
Animal models for liver disease - A practical approach for translational research.
细胞外囊泡在脂肪变性相关肝病中的作用及其治疗潜力。
World J Hepatol. 2024 Sep 27;16(9):1211-1228. doi: 10.4254/wjh.v16.i9.1211.
4
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.胰高血糖素样肽-1 受体:作用机制与治疗进展。
Signal Transduct Target Ther. 2024 Sep 18;9(1):234. doi: 10.1038/s41392-024-01931-z.
5
The role of FGF21 in the interplay between obesity and non-alcoholic fatty liver disease: a narrative review.成纤维细胞生长因子 21 在肥胖与非酒精性脂肪性肝病相互作用中的作用:一篇叙述性综述。
Rom J Morphol Embryol. 2024 Apr-Jun;65(2):159-172. doi: 10.47162/RJME.65.2.02.
6
The Root Extract of Ameliorates Nonalcoholic Steatohepatitis Development via Blockade of De Novo Lipogenesis and Inflammation.[某种植物]的根提取物通过阻断从头脂肪生成和炎症来改善非酒精性脂肪性肝炎的发展。 (注:原文中“The Root Extract of ”后缺少具体植物名称)
Curr Issues Mol Biol. 2024 Jun 12;46(6):5881-5893. doi: 10.3390/cimb46060351.
7
Autophagy and inflammation an intricate affair in the management of obesity and metabolic disorders: evidence for novel pharmacological strategies?自噬与炎症:肥胖和代谢紊乱管理中的复杂关系——新型药理学策略的证据?
Front Pharmacol. 2024 Jun 4;15:1407336. doi: 10.3389/fphar.2024.1407336. eCollection 2024.
8
Exploring autoantibodies as predictors of severe fibrosis or cirrhosis in metabolic dysfunction associated with steatotic liver disease.探索自身抗体作为脂肪性肝病相关代谢功能障碍中严重纤维化或肝硬化预测指标的作用。
Can Liver J. 2024 May 8;7(2):291-298. doi: 10.3138/canlivj-2023-0026. eCollection 2024 May.
9
Unlocking the Therapeutic Potential of Ellagic Acid for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.解锁鞣花酸对非酒精性脂肪性肝病和非酒精性脂肪性肝炎的治疗潜力。
Antioxidants (Basel). 2024 Apr 18;13(4):485. doi: 10.3390/antiox13040485.
10
The Reduced Gut Species Is Linked to Liver Enzyme Elevation and Insulin Resistance in Pediatric Fatty Liver Disease.肠道菌群减少与儿童非酒精性脂肪性肝病肝酶升高和胰岛素抵抗相关。
Int J Mol Sci. 2024 Mar 25;25(7):3640. doi: 10.3390/ijms25073640.
肝脏疾病的动物模型——转化研究的实用方法。
J Hepatol. 2020 Aug;73(2):423-440. doi: 10.1016/j.jhep.2020.04.011. Epub 2020 Apr 21.
4
Drug Therapy in Obesity: A Review of Current and Emerging Treatments.肥胖症的药物治疗:当前及新兴治疗方法综述
Diabetes Ther. 2020 Jun;11(6):1199-1216. doi: 10.1007/s13300-020-00816-y. Epub 2020 Apr 15.
5
Incretin combination therapy for the treatment of non-alcoholic steatohepatitis.肠促胰岛素联合治疗非酒精性脂肪性肝炎。
Diabetes Obes Metab. 2020 Aug;22(8):1328-1338. doi: 10.1111/dom.14035. Epub 2020 Apr 12.
6
Ghrelin-insulin-like growth factor-1 axis is activated via autonomic neural circuits in the non-alcoholic fatty liver disease.生长激素释放肽-胰岛素样生长因子 1 轴通过非酒精性脂肪性肝病的自主神经回路被激活。
Neurogastroenterol Motil. 2020 May;32(5):e13799. doi: 10.1111/nmo.13799. Epub 2020 Jan 27.
7
Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.二肽基肽酶-4 抑制作用可预防非酒精性脂肪性肝炎相关肝纤维化和肿瘤的发生,且其作用独立于其抗糖尿病作用。
Sci Rep. 2020 Jan 22;10(1):983. doi: 10.1038/s41598-020-57935-6.
8
Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病中的抗糖尿病药物与他汀类药物
J Clin Exp Hepatol. 2019 Nov-Dec;9(6):723-730. doi: 10.1016/j.jceh.2019.06.003. Epub 2019 Jun 27.
9
Protective Effect of α-Linolenic Acid on Non-Alcoholic Hepatic Steatosis and Interleukin-6 and -10 in Wistar Rats.α-亚麻酸对 Wistar 大鼠非酒精性肝脂肪变性及白细胞介素-6 和 -10 的保护作用。
Nutrients. 2019 Dec 18;12(1):9. doi: 10.3390/nu12010009.
10
Gastrointestinal peptides and nonalcoholic fatty liver disease.胃肠道肽与非酒精性脂肪性肝病。
Curr Opin Endocrinol Diabetes Obes. 2020 Feb;27(1):11-15. doi: 10.1097/MED.0000000000000514.